AstraZeneca's clot-fighter Brilinta shows promise in diabetics with heart disease in big study
As Pascal Soriot polishes the rough edges of his R&D shop within AstraZeneca, the British drugmaker reported some encouraging news that could help it expand the use of its clot-fighter Brilinta, once touted as a $3.5 billion-a-year treatment.
The drug, which generated roughly $1.3 billion last year and was one of AstraZeneca’s top ten medicines, was shown in 2017 — as part of a sub-group analysis — to induce a substantial 29% reduction in the risk of cardiovascular death in patients who had previously suffered a heart attack and who continued to take the treatment as well as aspirin past the first full year of therapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
